source
- Massachusetts biotech startups see funding gap widen as seed rounds shrink and Series A deals surgeA MassBio report shows that mature biotech firms in Massachusetts captured most of the venture capital in the first half of 2026, with nearly $3.5 billion invested, a 25% rise from the same period…
- Capricor secures reprieve as FDA extends DMD cell therapy reviewThe FDA has extended its review of Capricor Therapeutics’ Duchenne muscular dystrophy drug candidate, deferring the decision to review information the biotech submitted after a negative advisory co…Fierce Biotech · 4h ago↗ source
- FDA places second clinical hold on Regenxbio’s Hunter syndrome gene therapy after spinal masses detected